Huong T T Nguyen1, Zhen Xu1,2, Xiaofeng Shi1,3,4, Shuzhen Liu1,5, Marie L Schulte1, Gilbert C White1,6, Yan-Qing Ma1,2,6. 1. Versiti Blood Research Institute, Milwaukee, Wisconsin, USA. 2. Collaborative Research Program for Cell Adhesion Molecules, Shanghai University School of Life Sciences, Shanghai, China. 3. The second Affiliated Hospital of Nanjing Medical University, Nanjing, China. 4. The Affiliated Hospital of Jiangsu University, Zhenjiang, China. 5. The Affiliated Hospital of Qingdao University, Qingdao, China. 6. Department of Biochemistry, Medical College of Milwaukee, Milwaukee, Wisconsin, USA.
Abstract
BACKGROUND: Kindlin-3 is essential for supporting the bidirectional signaling of integrin αIIbβ3 in platelets by bridging the crosstalk between integrin αIIbβ3 and the cytoplasmic signaling adaptors. OBJECTIVE: In this study, we identified a previously unrecognized paxillin binding site in the pleckstrin homology (PH) domain of kindlin-3 and verified its functional significance. METHODS: Structure-based approaches were employed to identify the paxillin binding site in the PH domain of kindlin-3. In addition, the bidirectional signaling of integrin αIIbβ3 were evaluated in both human and mouse platelets. RESULTS: In brief, we found that a β1-β2 loop in the PH domain of kindlin-3, an important part of the canonical membrane phospholipid binding pocket, was also involved in mediating paxillin interaction. Interestingly, the binding sites of paxillin and membrane phospholipids in the PH domain of kindlin-3 were mutually exclusive. Specific disruption of paxillin binding to the PH domain by point mutations inhibited platelet spreading on immobilized fibrinogen while having no inhibition on soluble fibrinogen binding to stimulated platelets. In addition, a membrane-permeable peptide derived from the β1-β2 loop in the PH domain of kindlin-3 was capable of inhibiting platelet spreading and clot retraction, but it had no effect on soluble fibrinogen binding to platelets and platelet aggregation. Treatment with this peptide significantly reduced thrombus formation in mice. CONCLUSION: Taken together, these findings suggest that interaction between paxillin and the PH domain of kindlin-3 plays an important role in supporting integrin αIIbβ3 outside-in signaling in platelets, thus providing a novel antithrombotic target.
BACKGROUND: Kindlin-3 is essential for supporting the bidirectional signaling of integrin αIIbβ3 in platelets by bridging the crosstalk between integrin αIIbβ3 and the cytoplasmic signaling adaptors. OBJECTIVE: In this study, we identified a previously unrecognized paxillin binding site in the pleckstrin homology (PH) domain of kindlin-3 and verified its functional significance. METHODS: Structure-based approaches were employed to identify the paxillin binding site in the PH domain of kindlin-3. In addition, the bidirectional signaling of integrin αIIbβ3 were evaluated in both human and mouse platelets. RESULTS: In brief, we found that a β1-β2 loop in the PH domain of kindlin-3, an important part of the canonical membrane phospholipid binding pocket, was also involved in mediating paxillin interaction. Interestingly, the binding sites of paxillin and membrane phospholipids in the PH domain of kindlin-3 were mutually exclusive. Specific disruption of paxillin binding to the PH domain by point mutations inhibited platelet spreading on immobilized fibrinogen while having no inhibition on soluble fibrinogen binding to stimulated platelets. In addition, a membrane-permeable peptide derived from the β1-β2 loop in the PH domain of kindlin-3 was capable of inhibiting platelet spreading and clot retraction, but it had no effect on soluble fibrinogen binding to platelets and platelet aggregation. Treatment with this peptide significantly reduced thrombus formation in mice. CONCLUSION: Taken together, these findings suggest that interaction between paxillin and the PH domain of kindlin-3 plays an important role in supporting integrin αIIbβ3 outside-in signaling in platelets, thus providing a novel antithrombotic target.
Authors: Dawn H Siegel; Gabrielle H S Ashton; Homero G Penagos; James V Lee; Heidi S Feiler; Kirk C Wilhelmsen; Andrew P South; Frances J D Smith; Alan R Prescott; Vesarat Wessagowit; Noritaka Oyama; Masashi Akiyama; Daifullah Al Aboud; Khalid Al Aboud; Ahmad Al Githami; Khalid Al Hawsawi; Abla Al Ismaily; Raouf Al-Suwaid; David J Atherton; Ruggero Caputo; Jo-David Fine; Ilona J Frieden; Elaine Fuchs; Richard M Haber; Takashi Harada; Yasuo Kitajima; Susan B Mallory; Hideoki Ogawa; Sedef Sahin; Hiroshi Shimizu; Yasushi Suga; Gianluca Tadini; Kikuo Tsuchiya; Colin B Wiebe; Fenella Wojnarowska; Adel B Zaghloul; Takahiro Hamada; Rajeev Mallipeddi; Robin A J Eady; W H Irwin McLean; John A McGrath; Ervin H Epstein Journal: Am J Hum Genet Date: 2003-06-03 Impact factor: 11.025
Authors: Olga Vinogradova; Algirdas Velyvis; Asta Velyviene; Bin Hu; Thomas Haas; Edward Plow; Jun Qin Journal: Cell Date: 2002-09-06 Impact factor: 41.582
Authors: Markus Moser; Martina Bauer; Stephan Schmid; Raphael Ruppert; Sarah Schmidt; Michael Sixt; Hao-Ven Wang; Markus Sperandio; Reinhard Fässler Journal: Nat Med Date: 2009-02-22 Impact factor: 53.440
Authors: Nikolay L Malinin; Li Zhang; Jeongsuk Choi; Alieta Ciocea; Olga Razorenova; Yan-Qing Ma; Eugene A Podrez; Michael Tosi; Donald P Lennon; Arnold I Caplan; Susan B Shurin; Edward F Plow; Tatiana V Byzova Journal: Nat Med Date: 2009-02-22 Impact factor: 53.440
Authors: Huan Liu; Liang Zhu; Tejasvi Dudiki; Benjamin Gabanic; Logan Good; Eugene A Podrez; Olga A Cherepanova; Jun Qin; Tatiana V Byzova Journal: J Immunol Date: 2020-02-24 Impact factor: 5.422
Authors: Tao Ni; Antreas C Kalli; Fiona B Naughton; Luke A Yates; Omar Naneh; Mirijam Kozorog; Gregor Anderluh; Mark S P Sansom; Robert J C Gilbert Journal: Biochem J Date: 2016-12-14 Impact factor: 3.857